Medical staffing company AMN Healthcare reported 2017 fourth quarter revenue of $509 million, a 4 percent year-over-year increase.
San Diego’s Tandem Diabetes Care inked a European distribution deal with Rubin Medical, meaning its insulin pumps will be sold outside the U.S. for the first time.
DEVICES: Company Gains Advantage By Partnering With Insurer
Dexcom aspires to widen its reach beyond Type 1 diabetes. Recently, the San Diego company took a big step toward the goal.
The firm has two San Diego companies in its eight-company portfolio.
A first-ever test from San Diego’s Banyan Biomarkers to help doctors diagnose traumatic brain injuries has won Federal Drug Administration approval.
San Diego biotech Neurocrine reported a big increase in revenue following the launch of a nervous system drug in late spring, according to financial results released Feb. 13.
An Encinitas developer has struck a deal to buy Palomar Health’s downtown Escondido hospital campus for $18 million, paving the way for a mixed-use project that’s poised to be the epicenter of a construction boom in the area.
San Diego medical device maker Tandem Diabetes Care recently announced a $60 million public stock offering.
Sirenas, a marine-centric biotech in San Diego, has entered into a research agreement with pharmaceutical giant Bristol-Myers Squibb.
Seated beside an oval table in his office, Kevin Sayer squints to read a text on his phone. His blue eyes — the same color as his button-down shirt – light up.
San Diego-based MKO Global Partners has been acquired by Two Labs, which provides product and commercialization services to pharmaceutical manufacturers.
Joseph Payne is challenging the legality of Arcturus Therapeutics firing him as president and CEO of the company, according to a Feb. 6 letter filed with the U.S. Securities and Exchange Commission.
San Diego hospital systems have reported significant drops in operating income given a whirlwind of financial pressures.
The company said Feb. 2 that its board fired president and CEO Joseph Payne and named Mark Herbert as interim president.
OncoSec Medical, a San Diego biotech developing cancer therapies, announced on Feb. 1 a $20 million public stock offering.